Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Condition(s) studied

Investigational drug(s) / intervention(s)

Climen 21 Tablets: Climen is commonly used clinically as a hormone replacement therapy and was administered to all patients in both the control and experimental groups in this project.

hA-MSCs: The patients who were part of the experimental group were administered oral Clomid medication in conjunction with a combined intravenous injection of human amniotic MSCs.

Study summary

There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.

Eligibility

Primary outcome measure(s)

• Temperature — Up to 24 weeks
  Body temperature of the participants will be measured fortnightly after injection.
• Pulse — up to 24 weeks
  Pulse of the participants will be measured fortnightly after injection.
• Breaths per minute — up to 24 weeks
  Breathing rate of the participants will be measured fortnightly after injection.
• Blood pressure — 0-24 weeks
  Both systolic pressure and diastolic pressure of the participants will be assessed fortnightly after injection.

Trial sites (1)

Other trials for the same condition